Myriad COO’s Insider Sale Signals Confidence, Not Downturn
Myriad Genetics insider sale: COO Mark Verratti sells 1,069 shares amid rising stock but stable long‑term outlook—insight for investors.
3 minutes to read
Myriad Genetics Inc
Myriad Genetics Insider Sales Signal Strategic Portfolio Moves, Not Panic
Explore how Myriad Genetics’ insider sales reflect strategic portfolio moves—not distress signals—while the company expands diagnostics and partnerships in oncology and prenatal care.
3 minutes to read
Insider Buying Spurs Hope: Myriad’s Shares Rally on AI‑Driven Diagnostics and Strong Executive Support
Insider buys at $4.74 signal confidence in Myriad’s AI‑powered diagnostics and future growth, but regulatory and competitive risks still loom over its steeply discounted shares.
4 minutes to read